Kristie Kahl

Philadelphia

Vice President of Content at MJH Life Sciences

I'd rather be someone's shot of whiskey than everyone's cup of tea

Featured in: Favicon

mjhlifesciences.com Favicon

healio.com Favicon

newsbreak.com Favicon

ajmc.com

valdostadailytimes.com Favicon

heraldcourier.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

curetoday.com Favicon

dailyamerican.com + 7 more

Articles

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

2 weeks ago | curetoday.com | Kristie Kahl

It is crucial to understand the characteristics of the disease following a diagnosis of metastatic breast cancer, especially the cancers subtypes and associated biomarkers, as these directly impact the direction of treatment decisions. Moreover, advancements in treatment strategies within the therapeutic landscape aims to manage disease, control progression, as well as maintain quality of life for patients.
AI Tool May Predict Response, Resistance in Advanced RCC

2 weeks ago | oncnursingnews.com | Kristie Kahl

Tumor microenvironment signals and circulating factors may jointly influence treatment outcomes in patients with advanced renal cell carcinoma (RCC) who received nivolumab (Opdivo) plus cabozantinib (Cabometyx), according to David A Braun, MD, PhD.
Machine Learning-Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC

3 weeks ago | onclive.com | Kristie Kahl

Characteristics, including the state of the tumor microenvironment and circulating factors, could influence responses to nivolumab (Opdivo) plus cabozantinib (Cabometyx) in patients with advanced renal cell carcinoma, providing a potential framework for integrative analysis for biomarker discovery, according to David A. Braun, MD, PhD.
Addressing Complications from ADT Therapy to Treat Prostate Cancer

3 weeks ago | curetoday.com | Kristie Kahl

Androgen deprivation therapy (ADT), often referred to as hormonal therapy, is effective in slowing cancer growth among men with prostate cancer; however, maintaining quality of life in tandem with its side effects is important. ADT works by significantly lowering testosterone levels, a hormone vital for prostate cancer cell growth.
Machine Learning Approach May Predict Outcomes in RCC

3 weeks ago | cancernetwork.com | Kristie Kahl

The state of the tumor microenvironment and circulating factors together may influence response in patients with advanced renal cell carcinoma (RCC) who were treated with nivolumab (Opdivo) plus cabozantinib (Cabometyx), according to David A. Braun, MD, PhD.
Toripalimab Improves PFS in Bulky Unresectable Stage III NSCLC

3 weeks ago | targetedonc.com | Kristie Kahl

Toripalimab induction therapy plus chemotherapy for 2 cycles, compared with chemotherapy alone, followed by definitive chemoradiotherapy and consolidation, led to significantly improved progression-free survival (PFS) in patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC), according to data from the InTRist study (NCT05888402) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 “Toripalimab is a very promising strategy for patients...
Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

3 weeks ago | onclive.com | Kristie Kahl

Induction toripalimab plus chemotherapy for 2 cycles, compared with chemotherapy alone, followed by definitive chemoradiotherapy and consolidation, significantly improved progression-free survival (PFS) in patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC), according to data from the InTRist study (NCT05888402) presented at the 2025 ASCO Annual Meeting.1“Toripalimab is a very promising strategy for patients with bulky, unresectable tumors.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

3 weeks ago | onclive.com | Kristie Kahl

Treatment with sevabertinib (BAY 2927088) may lead to high and comparable objective response rates (ORRs) among patients with HER2-mutant non–small cell lung cancer (NSCLC) who were pretreated but naive to HER2-targeted therapy, or had not received any treatment for advanced disease, according to data from the phase 1/2 SOHO-01 trial (NCT05099172) presented at the 2025 ASCO Annual Meeting.
Fruquintinib Combo Exhibits Frontline Efficacy in Advanced ESCC

3 weeks ago | cancernetwork.com | Kristie Kahl

Fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin exhibited significant efficacy outcomes and an acceptable safety profile as a frontline treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a phase 2 study (NCT06010212) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

4 weeks ago | onclive.com | Kristie Kahl

Frontline treatment with fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin elicited responses with an acceptable safety profile in patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a phase 2 study (NCT06010212) presented during the 2025 ASCO Annual Meeting.